Office Resources | WAKIX® (pitolisant) for HCPs

Resources for You and Your Team

Telemedicine/symptom assessment

Telemedicine Guide

Guidance on conducting telemedicine interactions.

Symptom Assessment Guide

A guide for assessing excessive daytime sleepiness. Contains specific questions that may be particularly helpful for use in telemedicine, as well as guidance for Epworth Sleepiness Scale scoring and interpretation.

Download »

Assessing Ongoing Symptoms Guide

Specific questions to ask your patients with narcolepsy to help uncover excessive daytime sleepiness and cataplexy.

Download » Order »

Information about WAKIX

WAKIX Mechanism of Action Overview

Overview of how histamine works in the brain and its role in promoting and stabilizing wakefulness. Reviews how WAKIX is thought to work.

Download » Order »

WAKIX Clinical Data for EDS

Review data from clinical studies of WAKIX for the treatment of excessive daytime sleepiness in adults with narcolepsy.

Download » Order »

WAKIX Clinical Data for Cataplexy

Review data from clinical studies of WAKIX for the treatment of cataplexy in adults with narcolepsy.

Download » Order »

WAKIX Overview Brochure

Overview of clinical data and safety and tolerability profile for WAKIX.

Download » Order »

WAKIX Dosing Overview

Overview of the recommended dosing and titration for WAKIX, as well as setting patient expectations.

Download » Order »

Frequently Asked Questions About WAKIX

Review frequently asked questions and answers about WAKIX.

Download »

Resources for Prescribing WAKIX

WAKIX annotated prescription referral form

Guide for Completing the WAKIX Prescription
Referral Form

Annotated version of the WAKIX Prescription Referral Form to guide completion and avoid delays in processing.

Download »

WAKIX Prescription Referral Form

Downloadable form for writing a WAKIX prescription. Complete and submit the form to WAKIX for You.

Download » Order »

Resources for Your Patients

WAKIX Patient Brochure

Resource for patients with information about treatment with WAKIX for the management of excessive daytime sleepiness or cataplexy in adults with narcolepsy.

Download » Order »

Getting Started With WAKIX Card

Important information for patients about what they can expect when starting treatment with WAKIX.

Download » Order »

WAKIX for You Overview for Patients

Overview of the WAKIX for You patient support program, which helps facilitate access to therapy through reimbursement support, financial assistance, and coordination with the specialty pharmacy.

Download » Order »

WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy.

Contraindications

WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported. WAKIX is also contraindicated in patients with severe hepatic impairment.

Warnings and Precautions

WAKIX prolongs the QT interval; avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.
The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment (see full prescribing information). WAKIX is not recommended in patients with end-stage renal disease (ESRD).

Adverse Reactions

In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.

Drug Interactions

Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. Reduce the dose of WAKIX by half.
Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant by 50%. Dosage adjustments may be required (see full prescribing information).
H₁ receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX. Patients should avoid centrally acting H₁ receptor antagonists.
WAKIX is a borderline/weak inducer of CYP3A4. Therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX. The effectiveness of hormonal contraceptives may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy.

Use in Specific Populations

WAKIX may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuing treatment.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-800-833-7460.
The safety and effectiveness of WAKIX have not been established in patients less than 18 years of age.
WAKIX is extensively metabolized by the liver. WAKIX is contraindicated in patients with severe hepatic impairment. Dosage adjustment is required in patients with moderate hepatic impairment.
WAKIX is not recommended in patients with end-stage renal disease. Dosage adjustment of WAKIX is recommended in patients with moderate or severe renal impairment.
Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers; these patients have higher concentrations of WAKIX than normal CYP2D6 metabolizers.

To report suspected adverse reactions, contact Harmony Biosciences at 1-800-833-7460 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying
Full Prescribing Information.

AASM, American Academy of Sleep Medicine.
*	Clinical practice guideline on the treatment of central disorders of hypersomnolence, published in the Journal of Clinical Sleep Medicine, includes recommendations for treatment of narcolepsy in adults.